Sustained-release of SOD from multivesicular liposomes accelerated the colonic mucosal healing of colitis mice by inhibiting oxidative stress

• Published in: Colloids and surfaces, B, Biointerfaces B, Biointerfaces, 2024-11, Vol.243, p.114143, Article 114143
• Main Authors: Ran, Kunjie, Wang, Jie, Li, Dingwei, Jiang, Zhijiang, Ding, Bingyu, Yu, Fengnan, Hu, Sunkuan, Wang, Lifen, Sun, Wenwen, Xu, Helin
• Format: Article
• Language: English
• Subjects: Multivesicular liposome; Oxidative stress; Superoxide dismutase; Sustained release; Ulcerative colitis
• ISSN: 0927-7765; 1873-4367; 1873-4367
• DOI: 10.1016/j.colsurfb.2024.114143

Oxidative stress has long been known as a pathogenic factor of ulcerative colitis. Superoxide dismutase (SOD) has been demonstrated to mitigate gut mucosal injury via combating oxidative stress. Herein, we developed SOD-loaded multivesicular liposomes (S-MVLs) as sustained-release depot for ulcerative colitis treatment. S-MVLs were spherical honeycomb-like particles with average particle size of 27.3 ± 5.4 μm and encapsulating efficiency of 78.7 ± 2.6 %. Moreover, the two-phase release profiles of SOD from S-MVLs were exhibited, that was, the burst release phase within 4 h and the sustained-release phase within 96 h. After intraperitoneally injecting S-MVLs, in situ retention time of SOD at bowel cavity extended by 4-fold in comparison with SOD solution. In vitro cells experiment showed that S-MVLs had the protective effect on LPS-treated RAW 264.7 cells via scavenging ROS and inhibiting pro-inflammatory cytokines production. S-MVLs ameliorated the body weight loss, DAI score and the colon shortening of colitis mice. Meanwhile, the colonic morphology and the epithelial barrier of colitis mice were effectively recovered after S-MVLs treatment. The therapeutic mechanism might be associated with polymerizing M1 macrophages to M2 phenotypes and alleviating oxidative stress. Collectively, multivesicular liposomes might be a promising sustained-release depot of SOD for ulcerative colitis treatments. •Multivesicular liposomes was developed as sustained-release depot of SOD to prolong its short half-lives for ulcerative colitis treatment.•The burst release phase of SOD from S-MVLs were exhibited within 4 h, followed by the sustained-release phase within 96 h.•In situ retention time of S-MVLs at bowel cavity extended by 4-fold in comparison with SOD solution.•Moreover, the colonic morphology and the epithelial barrier of colitis mice were effectively recovered after S-MVLs treatment.•The therapeutic mechanism might be associated with polymerizing M1 macrophages to M2 phenotypes and alleviating oxidative stress.